Report
Guy Sips ...
  • Jeroen Van Den Bossche
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Morning Note: BEFB BB, DSM NA, FLOB BB, KIN BB, UCB BB

Befimmo: Accept the Offer
DSM: Acquires animal nutrition & tech company Prodap
Floridienne: Growth in sales and EBITDA in 1Q22
Kinepolis: Kinehold sells 0.66% to CEO/Bert family members
UCB: Bimzelx as the drug to beat in non-TNF responders
Underlyings
Befimmo SA

Befimmo is engaged in real estate investments. Co.'s activities are dedicated solely to the ownership and management of a real-estate portfolio. As of Dec. 30, 2012, the portfolio consisted principally of office buildings located in Brussels and let to public authorities or private businesses, and office buildings in various town centres in Flanders and Wallonia, let long-term to public authorities, and a building located in the city of Luxembourg.

Floridienne S.A.

Floridienne SA is a Belgium-based company engaged in the chemicals, gourmet food and life sciences sectors. The Chemicals division is engaged in two areas: additives for plastics used for stabilizing Polyvinyl Chloride and fireproofing plastics, as well as the recycling of nickel-cadmium, nickel-metal hydride and lithium-ion batteries. The Life Sciences division is active in the production and marketing of natural technologies and products that offer green and sustainable alternatives in agriculture, hygiene products and healthcare, among others. The Life Sciences division also provides plant proteases and integrated pest management. The Gourmet Food division is engaged in the production and marketing of party and gourmet food products such as snails, scallops, stuffed shellfish, smoked salmon, seafood salads, aperitif snacks and ethnic dishes. The Gourmet Food division also operates in the field of special needs foods, such as for people with deglutition problems, among others.

Koninklijke DSM N.V.

Royal DSM is engaged in the creation of products and services in Life Sciences and Materials Sciences. Co.'s products and services are used globally in range of markets and applications in healthcare, pharmaceutical automotive and chemicals sectors. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. The activities of Co. are grouped into four clusters: Nutrition, Pharma, Performance Materials and Polymer Intermediates.

UCB S.A.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Guy Sips

Jeroen Van Den Bossche

Thomas Vranken

Wim Hoste

Wim Lewi

Other Reports on these Companies
Other Reports from KBC Securities

ResearchPool Subscriptions

Get the most out of your insights

Get in touch